Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $10,950.72 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,111 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $3.52, for a total value of $10,950.72. Following the transaction, the chief technology officer now directly owns 1,753,370 shares in the company, valued at approximately $6,171,862.40. This represents a 0.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sight Sciences Trading Up 0.3 %

Shares of NASDAQ:SGHT opened at $3.32 on Thursday. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The company’s 50-day moving average price is $3.89 and its 200 day moving average price is $5.56. The company has a market cap of $168.51 million, a PE ratio of -3.25 and a beta of 2.57. Sight Sciences, Inc. has a fifty-two week low of $3.20 and a fifty-two week high of $8.45.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The company had revenue of $20.16 million for the quarter, compared to analysts’ expectations of $20.41 million. Sell-side analysts anticipate that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SGHT. JPMorgan Chase & Co. raised its stake in shares of Sight Sciences by 335.3% during the third quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company’s stock valued at $439,000 after purchasing an additional 53,658 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its position in shares of Sight Sciences by 5.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock worth $1,174,000 after buying an additional 10,000 shares in the last quarter. Barclays PLC lifted its stake in shares of Sight Sciences by 317.4% in the 3rd quarter. Barclays PLC now owns 50,300 shares of the company’s stock worth $317,000 after acquiring an additional 38,248 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Sight Sciences by 1.6% in the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after acquiring an additional 12,709 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after acquiring an additional 95,843 shares during the period. Institutional investors own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Piper Sandler restated a “neutral” rating and set a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Citigroup reduced their price target on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. UBS Group began coverage on shares of Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 price objective for the company. Morgan Stanley cut their target price on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, November 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Friday, November 8th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Sight Sciences presently has an average rating of “Hold” and a consensus price target of $5.12.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.